FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072398324> ?p ?o ?g. }

• W2072398324 endingPage "298" @default.
• W2072398324 startingPage "279" @default.
• W2072398324 abstract "To date, three isoforms of phospholipase A2 (PLA2) have been identified. Of these, the two Ca2+-dependent isoforms, secretory (sPLA2) and cytosolic phospholipase A2 (cPLA2), are targets for new anti-inflammatory drugs. The catalytic mechanisms and functions of the third isoform, Ca2+-independent cytosolic phospholipase A2 (iPLA2), are unknown at present. sPLA2 and cPLA2 are both implicated in the release of arachidonic acid and prophlogistic lipid mediators. However, recent findings provide evidence that cPLA2 is the dominant isoform in various kinds of inflammation, such as T-cell-mediated experimental arthritis. A triple function of PLA2-derived lipid mediators has been suggested: causing immediate inflammatory signs, involvement in secondary processes, e.g., superoxide free radical (O2) generation, apoptosis, or tumour necrosis factor-α (TNF-α)-cytotoxicity, and controlling the expression and activation of pivotal proteins implicated in inflammation and cell development, e.g., cytokines, adhesion proteins, proteinases, NF-κB, fos/jun/AP-1, c-Myc, or p21ras. In the past, research predominantly focused on the development of sPLA2 inhibitors; however, present techniques enable discrimination of cPLA2, sPLA2, and iPLA2, and specific inhibitors of each of the three isoforms are likely to appear soon. Over the last decade, between 40 and 50 sPLA2 inhibitors have been described; and the list is growing. However, of these, few have the potential for clinical success, and those that do are predominantly active site-directed inhibitors, e.g., BMS-181162, LY311727, ARL-67974, FPL67047, SB-203347, Ro-23-9358, YM-26734, and IS-741. At present, there are no likely clinical candidates emerging from the ranks of cPLA2 and iPLA2 inhibitors in development. Indications for which PLA2 inhibitors are being pursued include, sepsis, acute pancreatitis, inflammatory skin and bowel diseases, asthma, and rheumatoid arthritis. The three main obstacles to the successful development of PLA2 inhibitors include, insufficient oral bioavailability, low affinity for the enzyme corresponding to low in vivo efficacy and insufficient selectivity." @default.
• W2072398324 created "2016-06-24" @default.
• W2072398324 creator A5054317875 @default.
• W2072398324 date "1997-03-01" @default.
• W2072398324 modified "2023-10-17" @default.
• W2072398324 title "Phospholipase A2 inhibitors in development" @default.
• W2072398324 cites W142153101 @default.
• W2072398324 cites W1490728160 @default.
• W2072398324 cites W1499453816 @default.
• W2072398324 cites W1509650469 @default.
• W2072398324 cites W1532526998 @default.
• W2072398324 cites W1533950905 @default.
• W2072398324 cites W1554143159 @default.
• W2072398324 cites W1569457616 @default.
• W2072398324 cites W1696959307 @default.
• W2072398324 cites W1924092238 @default.
• W2072398324 cites W1966486888 @default.
• W2072398324 cites W1967291225 @default.
• W2072398324 cites W1967324212 @default.
• W2072398324 cites W1967890561 @default.
• W2072398324 cites W1968427039 @default.
• W2072398324 cites W1968786608 @default.
• W2072398324 cites W1988912173 @default.
• W2072398324 cites W1989396867 @default.
• W2072398324 cites W1992799550 @default.
• W2072398324 cites W1994821631 @default.
• W2072398324 cites W1994837082 @default.
• W2072398324 cites W1998928705 @default.
• W2072398324 cites W1999696720 @default.
• W2072398324 cites W2000545225 @default.
• W2072398324 cites W2002073339 @default.
• W2072398324 cites W2005149171 @default.
• W2072398324 cites W2012102849 @default.
• W2072398324 cites W2012397093 @default.
• W2072398324 cites W2013374425 @default.
• W2072398324 cites W2015942817 @default.
• W2072398324 cites W2016087238 @default.
• W2072398324 cites W2022037486 @default.
• W2072398324 cites W2026142044 @default.
• W2072398324 cites W2030967377 @default.
• W2072398324 cites W2032273347 @default.
• W2072398324 cites W2032835730 @default.
• W2072398324 cites W2039672307 @default.
• W2072398324 cites W2040220172 @default.
• W2072398324 cites W2041445461 @default.
• W2072398324 cites W2044535743 @default.
• W2072398324 cites W2046458530 @default.
• W2072398324 cites W2051736472 @default.
• W2072398324 cites W2051958752 @default.
• W2072398324 cites W2055354280 @default.
• W2072398324 cites W2060241486 @default.
• W2072398324 cites W2061436315 @default.
• W2072398324 cites W2063271940 @default.
• W2072398324 cites W2065866797 @default.
• W2072398324 cites W2068812175 @default.
• W2072398324 cites W2069628646 @default.
• W2072398324 cites W2071115174 @default.
• W2072398324 cites W2071957781 @default.
• W2072398324 cites W2074593407 @default.
• W2072398324 cites W2078386027 @default.
• W2072398324 cites W2085341865 @default.
• W2072398324 cites W2086098722 @default.
• W2072398324 cites W2087411894 @default.
• W2072398324 cites W2091242257 @default.
• W2072398324 cites W2092140782 @default.
• W2072398324 cites W2092308058 @default.
• W2072398324 cites W2092717485 @default.
• W2072398324 cites W2093090071 @default.
• W2072398324 cites W2093903163 @default.
• W2072398324 cites W2096985979 @default.
• W2072398324 cites W2111381334 @default.
• W2072398324 cites W2119060894 @default.
• W2072398324 cites W2119065495 @default.
• W2072398324 cites W2122417664 @default.
• W2072398324 cites W2146388445 @default.
• W2072398324 cites W2149119522 @default.
• W2072398324 cites W2152100946 @default.
• W2072398324 cites W2153191634 @default.
• W2072398324 cites W2161169364 @default.
• W2072398324 cites W2161610230 @default.
• W2072398324 cites W2163641593 @default.
• W2072398324 cites W2185765170 @default.
• W2072398324 cites W221489722 @default.
• W2072398324 cites W2279334259 @default.
• W2072398324 cites W2315586839 @default.
• W2072398324 cites W2463254243 @default.
• W2072398324 cites W257848480 @default.
• W2072398324 cites W2951039765 @default.
• W2072398324 cites W4243763482 @default.
• W2072398324 doi "https://doi.org/10.1517/13543784.6.3.279" @default.
• W2072398324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15989628" @default.
• W2072398324 hasPublicationYear "1997" @default.
• W2072398324 type Work @default.
• W2072398324 sameAs 2072398324 @default.
• W2072398324 citedByCount "25" @default.
• W2072398324 countsByYear W20723983242012 @default.
• W2072398324 countsByYear W20723983242015 @default.
• W2072398324 countsByYear W20723983242018 @default.

• next